Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPONA study of platinum + pemetrexed with or without osimertinib in EGFR-mutant NSCLC with brain metastases after systemic progression on osimertinib
jRCTs071200029Recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of osimertinib, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Oct 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs071200029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071200029.